16th May 2011 14:30
16 May 2011 Silence Therapeutics plc ("Silence Therapeutics" or the "Company") Result of General Meeting
Silence announces that at its General Meeting held earlier today, the resolutions as set out in the circular sent to shareholders on 27 April 2011 in reference to the Placing and Open Offer which has raised £5.9 million, were duly passed.
Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of the 296,693,065 New Ordinary Shares. It is expected that Admission will become effective on 17 May 2011 and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 17 May 2011. Following Admission, the Company will have 576,584,517 Ordinary Shares in issue.
For more information, please contact:
Silence Therapeutics plc Tel: +44 (0)20 7491 6520 Jerry Randall, Chairman Phil Haworth, CEO Max Herrmann, CFO Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500 Shaun Dobson Claes Sp¥ng M: Communications (Europe) Tel: +44 (0)20 7920 2345 Katja Toon Emma Thompson --Ends--
vendorRelated Shares:
SLN.L